Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089361 · ClinicalTrials.gov registry record · Phase 1
Immunomodulatory Properties of Ketamine in Sepsis
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01089361 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 19 participants.
The verdict
NCT01089361, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortality.
Interventions
- DRUG Ketamine
- DRUG Normal Saline placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089361
The ClinicalTrials.gov registry entry for NCT01089361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01089361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089361 about?
NCT01089361 is a clinical study titled "Immunomodulatory Properties of Ketamine in Sepsis". The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortalit...
What is the current status of trial NCT01089361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2009-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01089361?
The interventions under investigation include: Ketamine (DRUG), Normal Saline placebo (DRUG).
Who is sponsoring clinical trial NCT01089361?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.